GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

BridgeBio Pharma BBIO · USD

Health Care · US listing · 🇺🇸 United States

Compare

77.93

+4.90%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$502.1m

FY2017FY2025

Net income

−$729.3m

FY2017FY2025

Free cash flow

−$447.0m

FY2017FY2025

Shareholders' equity

−$2.08bn

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue$502.1m$221.9m$9.3m$77.6m$69.7m$8.2m$40.6m——
Gross profit$473.8m$218.0m$6.9m$74.2m$66.6m$8.2m$38.1m—−$260,000
Research and development$477.5m$506.5m$455.7m$399.5m$451.0m$337.0m$209.9m$140.1m$30.6m
Operating income−$576.6m−$593.0m−$590.0m−$512.2m−$540.8m−$472.8m−$266.2m−$183.7m−$43.9m
Net income−$729.3m−$535.8m−$643.2m−$481.2m−$562.5m−$448.7m−$260.4m−$130.7m−$30.6m
Diluted earnings per share-3.70-2.83-3.69-3.22-3.87-3.77-2.21-1.42-0.99

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$936.0m$919.3m$546.4m$623.0m$1.01bn$703.6m$631.7m$464.9m$98.0m
Cash and short-term investments$587.5m$681.1m$434.9m$471.9m$836.7m$607.1m$546.0m$436.1m$92.0m
Total liabilities$3.01bn$2.38bn$1.89bn$1.87bn$1.88bn$595.7m$155.7m$566.4m$152.7m
Debt$1.87bn$2.20bn$1.73bn$1.71bn$1.71bn$479.0m$91.8m$54.5m—
Shareholders' equity−$2.08bn−$1.47bn−$1.35bn−$1.25bn−$870.4m$57.9m$408.5m−$164.0m−$58.0m
Shares outstanding197m189m174m149m145m119m118m92m31m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−$445.9m−$520.7m−$527.7m−$419.5m−$497.9m−$399.7m−$253.6m−$136.6m−$40.5m
Capital spending−$1.1m−$933,000−$1.3m−$6.3m−$48.2m−$7.5m−$5.1m−$18.2m−$464,000
Free cash flow−$447.0m−$521.7m−$529.0m−$425.8m−$546.2m−$407.2m−$258.7m−$154.8m−$41.0m
Dividends paid————−$3.8m−$537.0m−$997,000—−$1.2m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$208.5m$194.5m$154.2m$120.7m$110.6m$116.6m$5.9m$2.7m
Gross profit$212.2m$184.1m$138.8m$114.1m$106.9m$114.0m$3.8m$2.1m
Operating income−$107.1m−$113.7m−$151.3m−$144.6m−$144.0m−$127.5m−$236.4m−$191.8m
Net income−$152.2m−$164.0m−$197.2m−$182.7m−$181.9m−$167.4m−$265.1m−$162.0m
Diluted earnings per share-0.78-0.84-1.00-0.93-0.92-0.85-1.40-0.86
Cash from operations−$71.0m−$197.0m−$56.0m−$109.0m−$80.0m−$199.0m−$195.0m−$180.0m
Capital spending——−$4.0m—−$5.0m−$1.0m−$3.0m−$1.0m
Free cash flow——−$60.0m—−$85.0m−$200.0m−$198.0m−$181.0m
Total assets$1.22bn$1.37bn$936.0m$998.3m$1.08bn$881.6m$919.3m$665.0m
Cash and short-term investments$720.2m$940.2m$587.5m$645.9m$757.3m$540.6m$681.1m$266.3m
Debt$18.3m$2.50bn$1.87bn$1.86bn$1.86bn$1.85bn$1.73bn$1.72bn
Shareholders' equity−$2.51bn−$2.27bn−$2.08bn−$1.93bn−$1.79bn−$1.65bn−$1.47bn−$1.23bn

Financial ratios

Data as of 1 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin94.4%98.3%73.7%95.6%95.5%100.0%
Operating margin-114.8%-267.2%-6342.0%-659.6%-775.7%-5732.2%
Net margin-145.3%-241.4%-6913.9%-619.7%-806.9%-5439.7%
Return on equity35.1%36.5%47.5%38.4%64.6%-774.9%
Return on assets-77.9%-58.3%-117.7%-77.2%-55.5%-63.8%
Free cash flow yield-3.4%-4.2%-4.6%-4.2%-4.7%-5.0%
Revenue growth126.3%2285.3%-88.0%11.4%745.1%-79.7%
Earnings growth36.1%-16.7%33.7%-14.5%25.4%72.3%
Current ratio2.62x4.67x3.32x4.52x6.58x6.72x
Debt to equity-0.90x-1.18x-1.28x-1.36x-1.96x8.31x
Equity ratio-221.9%-159.7%-247.9%-201.4%-85.9%8.2%
Interest coverage-10.86x-5.97x-7.26x-6.37x-11.56x-12.90x
R&D as a share of sales95.1%228.2%4898.5%514.5%646.9%4085.9%
Buybacks as a share of market value-4.1%-8.6%-16.8%-2.8%-22.1%-1.1%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue86.3%127.4%—
Operating income4.0%4.0%—
Net income14.9%10.2%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin95.6%95.3%95.4%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Price to earnings-20.7-9.7-10.9-2.4-4.3-5.3-4.4
Price to sales30.123.4—14.734.8287.428.5

Market value over time

28 Jun 2019 to 30 Sept 2026, in USD

$2.48bn$12.88bn

Share price return

Finished calendar years

2025202420232022202120202019
Return185%-35%371%-26%-37%58%51%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.